Placental Protein 13: Vasomodulatory Effects on Human Uterine Arteries and Potential Implications for Preeclampsia
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147522 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mariacarmela Gatto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Ecology and Earth Sciences, University of Calabria, 87036 Rende, Italy. Hauptthemen laut MEDLINE: Pre-Eclampsia, Uterine Artery, Pregnancy Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Icelandic Technology, ASPRE Project EU.
Abstract (Originalsprache)
Placental protein 13 (PP13) exhibits a plasma concentration that increases gradually during normal gestation, a process that is disrupted in preeclampsia, which is characterized by elevated vascular resistance, reduced utero-placental blood flow, and intrauterine growth restriction. This study investigated PP13’s role in vascular tone regulation and its molecular mechanisms. Uterine and subcutaneous arteries, isolated from both pregnant and non-pregnant women, were precontracted with the thromboxane analogue U46619 and exposed to PP13 using pressurized myography. The molecular mechanisms were further investigated, using specific inhibitors for nitric oxide synthase (L-NAME+LNNA at 10−4 M) and guanylate cyclase (ODQ at 10−5 M). The results showed that PP13 induced vasodilation in uterine arteries, but not in subcutaneous arteries. Additionally, PP13 counteracted U46619-induced vasoconstriction, which is particularly pronounced in pregnancy. Further investigation revealed that PP13’s mechanism of action is dependent on the activation of the nitric oxide–cGMP pathway. This study provides novel insights into the vasomodulatory effects of PP13 on human uterine arteries, underscoring its potential role in regulating utero-placental blood flow. These findings suggest that PP13 may be a promising candidate for improving utero-placental blood flow in conditions such as preeclampsia. Further research and clinical studies are warranted to validate PP13’s efficacy and safety as a therapeutic agent for managing preeclampsia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Ecology and Earth Sciences, University of Calabria, 87036 Rende, Italy.
- Department of Gynecology and Obstetrics, Hospital SS Annunziata, 87100 Cosenza, Italy.
- Faculty of Pharmaceutical Sciences, University of Iceland, 101 Reykjavik, Iceland.
- Hylabs Ltd., Rehovot 7670606, Israel.
- TeleMarpe Ltd., Tel Aviv 6908742, Israel.
- Department of Obstetrics, Gynecology and Reproductive Sciences, Larner College of Medicine, University of Vermont, Burlington, VT 05401, USA.
ORCID-Profile: Milena Esposito, Michele Morelli, Sveinbjorn Gizurarson, Maurizio Mandalà
Förderung
- Icelandic Technology
- ASPRE Project EU
Zitieren
APA
Gatto, M., Esposito, M., Morelli, M., De Rose, S., Gizurarson, S., Meiri, H., & Mandalà, M. (2024). Placental Protein 13: Vasomodulatory Effects on Human Uterine Arteries and Potential Implications for Preeclampsia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147522
Vancouver
Gatto M, Esposito M, Morelli M, De Rose S, Gizurarson S, Meiri H, et al. Placental Protein 13: Vasomodulatory Effects on Human Uterine Arteries and Potential Implications for Preeclampsia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147522
BibTeX
@article{Gatto2024,
author = {Gatto, Mariacarmela and Esposito, Milena and Morelli, Michele and De Rose, Silvia and Gizurarson, Sveinbjorn and Meiri, Hamutal and Mandalà, Maurizio},
title = {Placental Protein 13: Vasomodulatory Effects on Human Uterine Arteries and Potential Implications for Preeclampsia},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147522}
}
EUVIMED